Documents & Presentations
SEC Filings
General Meeting October 2026
Annual General Meeting
Notice of Annual General Meeting November 2026
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Notice of Annual General Meeting October 2025
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Notice of Annual General Meeting October 2024
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Notice of Annual General Meeting November 2023
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Presentations
H.C. Wainwright 28th Annual Global Investment Conference
Scancell Financial Year 2026 Interim Results
ESMO IO: Refining Standard of Care in Advanced Melanoma
CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive
SCOPE Data Update: 11 December 2025
Presentation of Year End Results: 11 September 2025
Scancell CEO on 2025 Milestones and Road ahead
Scancell Financial Year End 2025 Results
Scancell reports Strong Phase 2 Data on iSCIB1+ in Advanced Melanoma
Active Immunotherapy for a Cancer-Free Future
Clinical & Corporate Update: Active Immunotherapy for a Cancer-Free Future
Investor Update: 24 April 2025
Scancell’s new partnership with the NHS Vaccine Launch Pad (CLVP) March 2025
Trinity Delta Reports
Atlantic crossing transforms outlook
Strategic transactions to unlock longer-term value
iSCIB1+ pivotal trial plans advancing
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
H126: solid iSCIB1+ data underpins planned progress
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
FDA clears global Phase III trial for iSCIB1+
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Latest SCOPE data confirm durable improvement
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Abundant development opportunities in immuno-oncology
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Full steam ahead with iSCIB1+
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
SCOPE’ing out iSCIB1+ in advanced melanoma
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Successful SCOPE outcome and iSCIB1+ selection
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Cancer vaccine data due soon; Glymab developments too
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
H125 reaffirms funds are sufficient to deliver key data
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Poised for several pivotal clinical events in 2025
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Fundraise extends cash into H226 beyond key catalysts
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Genmab strikes second GlyMab deal
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Analysts' Reports
Edison Report – Redesigning immunity: The next frontier in immuno-oncology
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!